<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        282-212-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MONTEL 10MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Organon Pharma (UK) Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Organon Pharma (UK) Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MONTEL is a leukotriene receptor antagonist that blocks substances called leukotrienes.</p><p>Leukotrienes cause narrowing and swelling of airways in the lungs and also cause allergy</p><p>symptoms. By blocking leukotrienes, MONTEL improves asthma symptoms, helps control</p><p>asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic</p><p>rhinitis).</p><p>Your doctor has prescribed MONTEL to treat asthma, preventing your asthma symptoms during</p><p>the day and night.</p><ul><li>MONTEL is used for the treatment of patients who are not adequately controlled on their medication and need additional therapy.</li><li>MONTEL also helps prevent the narrowing of airways triggered by exercise.</li><li>In those asthmatic patients in whom MONTEL is indicated in asthma, MONTEL can also</li></ul><p>provide symptomatic relief of seasonal allergic rhinitis.</p><ul><li>Your doctor will determine how MONTEL should be used depending on the symptoms and severity of your asthma.</li><li>MONTEL is used to treat outdoor allergies that happen part of the year (seasonal allergic rhinitis) in adults and adolescents 15 years of age and older</li><li>MONTEL is used to treat indoor allergies that happen all year (perennial allergic rhinitis) in adults and adolescents 15 years of age and older</li></ul><p><strong>What is asthma?</strong></p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><p>&bull; difficulty breathing because of narrowed airways. This narrowing of airways</p><p>worsens and improves in response to various conditions.</p><p>&bull; sensitive airways that react to many things, such as cigarette smoke, pollen,</p><p>or cold air, or exercise.</p><p>&bull; swelling (inflammation) in the lining of airways.</p><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p><p><strong>What are seasonal allergies?</strong></p><p>Seasonal allergies (also known as hay fever or seasonal allergic rhinitis) are an allergic response</p><p>often caused by airborne pollens from trees, grasses and weeds. The symptoms of seasonal</p><p>allergies typically may include: stuffy, runny, itchy nose; sneezing; watery, swollen, red, itchy</p><p>eyes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies you have now or have had.</p><p><strong>Do not take MONTEL if you</strong></p><p>&bull; are allergic (hypersensitive) to montelukast or any of the other ingredients of</p><p>MONTEL(see 6. FURTHER INFORMATION).</p><p><strong>Take special care with MONTEL</strong></p><p>&bull; If your asthma or breathing gets worse, tell your doctor immediately.</p><p>&bull; Oral MONTEL is not meant to treat acute asthma attacks. If an attack occurs, follow the</p><p>instructions your doctor has given you. Always have your inhaled rescue medicine for</p><p>asthma attacks with you.</p><p>&bull; It is important that you or your child take all asthma medications prescribed by your</p><p>doctor. MONTEL should not be substituted for other asthma medications your doctor has</p><p>prescribed for you.</p><p>&bull; Any patient on anti-asthma medicines should be aware that if you develop a combination</p><p>of symptoms such as a flu-like illness, pins and needles or numbness of arms or legs,</p><p>worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&bull; You should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also</p><p>known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your asthma</p><p>worse.</p><p>Patients should be aware that various neuropsychiatric events (for example behaviour and moodrelated changes) have been reported in adults, adolescents and children with MONTEL (see section 4).</p><p>If you develop such symptoms while taking MONTEL, you should consult your doctor.</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children less than 15 years of age.</p><p>There are different form(s) of this medicine available for paediatric patients under 18 years of age based on age range.</p><p><strong>Taking other medicines</strong></p><p>Some medicines may affect how MONTEL works, or MONTEL may affect how other medicines</p><p>work.</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken other medicines,</p><p>including those obtained without a prescription.</p><p>Tell your doctor if you are taking the following medicines before starting MONTEL:</p><p>&bull; phenobarbital (used for treatment of epilepsy)</p><p>&bull; phenytoin (used for treatment of epilepsy)</p><p>&bull; rifampicin (used to treat tuberculosis and some other infections)</p><p>&bull; gemfibrozil (used for treatment of high lipid levels in plasma)</p><p><strong>Taking MONTEL with food and drink</strong></p><p>MONTEL 10 mg may be taken with or without food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><em>Use in pregnancy</em></p><p>Women who are pregnant or intend to become pregnant should consult their doctor before taking</p><p>MONTEL. Your doctor will assess whether you can take MONTEL during this time.</p><p><em>Use in breast-feeding</em></p><p>It is not known if MONTEL appears in breast milk. You should consult your doctor before</p><p>taking MONTEL if you are breast-feeding or intend to breast-feed.</p><p><strong>Driving and using machines</strong></p><p>MONTEL is not expected to affect your ability to drive a car or operate machinery. However,</p><p>individual responses to medication may vary. Certain side effects (such as dizziness and</p><p>drowsiness) that have been reported very rarely with MONTEL may affect some patients&rsquo; ability</p><p>to drive or operate machinery.</p><p><strong>Important information about some of the ingredients of MONTEL</strong></p><p>MONTEL10 mg film-coated tablets contain lactose. If you have been told by your doctor that</p><p>you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; You should take only one tablet of MONTEL once a day as prescribed by your doctor.</p><p>&bull; It should be taken even when you have no symptoms or have an acute asthma attack.</p><p>&bull; Always take MONTEL as your doctor has told you. You should check with your doctor or</p><p>pharmacist if you are not sure.</p><p>&bull; To be taken by mouth.</p><p><strong>For adults 15 years of age and older:</strong></p><p>One 10 mg tablet to be taken daily in the evening. MONTEL10 mg may be taken with or without</p><p>food.</p><p>If you are taking MONTEL, be sure that you do not take any other products that contain the</p><p>same active ingredient, montelukast.</p><p><strong>If you take more MONTEL than you should</strong></p><p>Contact your doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently</p><p>occurring symptoms reported with overdose in adults and children included abdominal pain,</p><p>sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p><strong>If you forget to take MONTEL</strong></p><p>Try to take MONTEL as prescribed. However, if you miss a dose, just resume the usual schedule</p><p>of one tablet once daily.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking MONTEL</strong></p><p>MONTEL can treat your asthma only if you continue to take it.</p><p>It is important to continue taking MONTEL for as long as your doctor prescribes. It will help</p><p>control your asthma.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies with MONTEL 10 mg film-coated tablets, the most commonly reported side effects (may affect up to 1 in 10 people) thought to be related to MONTEL were:</p><p>&bull; abdominal pain</p><p>&bull; headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with MONTEL than placebo (a pill containing no medication).</p><p><strong>Serious side effects</strong></p><p><strong>Talk with your doctor immediately </strong>if you notice any of the following side effects, which may be serious, and for which you may need urgent medical treatment.</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause</p><p>difficulty in breathing or swallowing</p><p>&bull; behaviour and mood related changes: agitation including aggressive behaviour or hostility, depression</p><p>&bull; seizure</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; increased bleeding tendency</p><p>&bull; tremor</p><p>&bull; palpitations</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)</p><p>&bull; low blood platelet count</p><p>&bull; behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and</p><p>actions</p><p>&bull; swelling (inflammation) of the lungs</p><p>&bull; severe skin reactions (erythema multiforme) that may occur without warning</p><p>&bull; inflammation of the liver (hepatitis)</p><p><strong>Other side effects while the medicine has been on the market</strong></p><p>Very common: the following may affect more than 1 in 10 people</p><p>&bull; upper respiratory infection</p><p>Common: the following may affect up to 1 in 10 people</p><p>&bull; diarrhoea, nausea, vomiting</p><p>&bull; rash</p><p>&bull; fever</p><p>&bull; elevated liver enzymes</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; behaviour and mood related changes: dream abnormalities, including nightmares, trouble</p><p>sleeping, sleepwalking, irritability, feeling anxious, restlessness</p><p>&bull; dizziness, drowsiness, pins and needles/numbness</p><p>&bull; nosebleed</p><p>&bull; dry mouth, indigestion</p><p>&bull; bruising, itching, hives</p><p>&bull; joint or muscle pain, muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bedwetting in children</p><p>&bull; weakness/tiredness, feeling unwell, swelling</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; behaviour and mood related changes: disturbance in attention, memory impairment, uncontrolled muscle movements</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; tender red lumps under the skin, most commonly on your shins (erythema nodosum)</p><p>&bull; behaviour and mood related changes: obsessive-compulsive symptoms, stuttering</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30&deg;C.</p><p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use this medicine after the date shown by the six numbers following EXP on the</p><p>blister. The first two numbers indicate the month; the last four numbers indicate the year.</p><p>This medicine expires at the end of the month shown.</p><p>&bull; Store in the original package in order to protect from light and moisture.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your</p><p>pharmacist how to dispose of medicines no longer required. These measures will help to</p><p>protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is montelukast. Each tablet contains montelukast sodium which</p><p>corresponds to 10 mg of montelukast.</p><p>&bull; The other ingredients are:</p><p>Microcrystalline cellulose, lactose monohydrate (89,3 mg), croscarmellose sodium,</p><p>hyprolose (E 463), and magnesium stearate.</p><p>Film coating: hypromellose, hyprolose (E 463), titanium dioxide (E 171), red and yellow</p><p>ferric oxide (E 172), and carnauba wax.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10 mg MONTEL tablets are Film-coated tablet.
Beige, rounded square, film-coated, size 7.9 mm x 7.9 mm with 117 engraved on one side.
Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 84, 90, 98, 100, 140, and 200 tablets.
Blisters (unit does), in packages of: 49, 50 and 56 tablets
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>Organon Pharma (UK) Limited, Shotton Lane,</p><p>Cramlington, Northumberland, NE23 3JU,</p><p>UK.</p><p><strong>Marketing Authorization Holder </strong></p><p><strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">مونتيل عبارة عن مضاد لمستقبلات الليوكوترايين والتي تمنع مواد تدعى الليوكوترايين. الليوكوترايينات تسبب</p><p dir="RTL">ضيق وتورم مجرى التنفس في الرئتين وتسبب أيضاً أعراض الحساسية. وبمنع الليوكوترايين، فإن مونتيل يحسن</p><p dir="RTL">أعراض الربو، ويساعد على السيطرة على الربو ويحسن أعراض الحساسية الموسمي (والتي تعرف بحمى القش</p><p dir="RTL">أو سيلان الأنف التحسسي الموسمي)</p><p dir="RTL">لقد وصف لك الطبيب مونتيل لعلاج الربو، ولمنع ظهور أعراض الربو أثناء النهار والليل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ويستخدم مونتيل لعلاج المرضى الذين لا يستجيبون وبصورة كافية لأدوية الربو التي يستخدمونها و بالتالي فهم بحاجة لعلاج إضافي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد مونتيل أيضاً على منع تضيق مجاري التنفس التي تتهيج بأداء التمارين الرياضية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في مرضى الربو الذين يستخدمون مونتيل لعلاج الربو، فإن مونتيل يؤدي إلى تخفيف أعراض حساسية الأنف الموسمية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيحدد لك الطبيب كيف تستخدم مونتيل إعتماداً على الأعراض وعلى شدة مرض الربو لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدَم مونتيل لمعالجة الحساسية التي تحدث في الهواء الطلق خلال جزء من السنة (حساسية الأنف الموسمية) لدى البالغين والمراهقين من سن 15 سنة من العمر فما أكبر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدَم مونتيل لمعالجة الحساسية التي تحدث في الداخل طوال العام (التهاب الأنف التحسسي الدائم) لدى البالغين والمراهقين 15 سنة من العمر فما أكبر.<strong> </strong></p><p dir="RTL"><strong>ماهو</strong><strong> </strong><strong>الربو؟</strong></p><p dir="RTL">الربو هو مرض رئوي مزمن.</p><p dir="RTL">ويشمل مرض الربو ما يلي:</p><p dir="RTL">&bull; صعوبة التنفس بسبب ضيق في مجاري التنفس. ويزداد هذا الضيق سوءاً أو يتحسن نتيجة لحالات مختلفة.</p><p dir="RTL">&bull; مجري التنفس الحساس يتأثر بالعديد من المؤثرات، مثل دخان السجائر, حبوب اللقاح, برودة الجو, أو التمارين الرياضية.</p><p dir="RTL">&bull; تورم) التهاب) بطانة مجرى التنفس.</p><p dir="RTL">وتشمل أعراض الربو ما يلي: السعال, أزيز وضيق في الصدر.</p><p dir="RTL"><strong>ماهي</strong><strong> </strong><strong>الحساسية</strong><strong> </strong><strong>الموسمية؟</strong></p><p dir="RTL">الحساسية الموسمية) تعرف أيضاً بحمى القش أو حساسية الأنف الموسمية) هي الإستجابة للحساسية التي تحدث بسبب حبوب اللقاح المتطايرة في الهواء من الأشجار, العشب, والأعشاب الضارة. أعراض الحساسية الموسمية قد تشمل: إحتقان, سيلان, &nbsp;حكة الأنف, عطس, تدميع, تورم, وحكة العينين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك إذا كنت تعاني من مشاكل طبية أو حساسية الآن أو أصبت بها مسبقاً.</p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>مونتيل</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong></p><p dir="RTL">&bull; مصاباً بفرط الحساسية لمونتيلوكاست أو أي من المواد الموجودة في مونتيل (انظر فقرة 6. معلومات</p><p dir="RTL">إضافية(</p><p dir="RTL"><strong>اتبع</strong><strong> </strong><strong>عناية</strong><strong> </strong><strong>خاصة</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>مونتيل</strong></p><p dir="RTL">&bull; إذا تدهورت حالة الربو لديك فأخبر طبيبك على الفور.</p><p dir="RTL">&bull; لا يقصد بمونتيل الفموي كعلاج لنوبات الربو المفاجئة. إذا حدثت النوبة, اتبع تعليمات الطبيب التي ذكرها لك. ومن المهم أن يكون دواء الإنقاذ السريع المستنشق للربو جاهزاً معك.</p><p dir="RTL">&bull; من المهم أن تتناول أنت أو ابنك جميع أدوية الربو التي وصفها الطبيب حسب حاجتها, ولا يجب الاستعاضة بمونتيل عن أدوية الربو الأخرى التي وصفها لك الطبيب.</p><p dir="RTL">&bull; أي مريض يتناول أدوية الربو يجب أن يتنبه عند حدوث مجموعة من الأعراض مثل مرض يشبه مرض الإنفلونزا, الشعور بوخز أو خدر في الذراعين أوالساقين, تدهور الأعراض الصدرية, و/أو طفح فضلاً استشر الطبيب.</p><p dir="RTL">&bull; يجب أن تتجنب استخدام حمض الأسيتايل ساليسيليك (الأسبرين) أو الأدوية الأخرى المضادة للالتهاب الغير ستيرويدية &nbsp;والتي تعرف أيضاً بمضادات الإلتهاب الغير ستيرويدية أو (NSAIDs) إذا أدت إلى تدهور حالة الربو لديك.</p><p dir="RTL">ينبغي أ ن يدرك المرضى ﺑﺄنه تم الإبلاغ عن الأحداث العصبية النفسية المختلفة (علي سبيل المثال, السلوك و التغيرات المتعلقة ﺑﺎلمزاج) لدى البالغين والمراهقين والأطفال مع مونتيل (انظر القسم 4). إذا كنت تواجه مثل هذه الأعراض أثناء تناول مونتيل، يجب استشارة الطبيب.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعطِ الدواء للأطفال أقل من عمر 15 عام.</p><p dir="RTL">هناك أ شكال صيدلانية مختلفة لهذا الدواء للمرضى الأطفال تحت عمر 18 سنة على أساس الفئة العمرية<strong> </strong></p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong>:</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على طريقة عمل مونتيل، أو قد يؤثر مونتيل على طريقة عمل الأدوية الأخرى.</p><p dir="RTL">يجب أن تخبر طبيبك أو الصيدلي عن جميع الأدوية التي تتناولها أو تناولتها حديثاً, بما ذلك الأدوية التي تحصل عليها بدون وصفة طبية.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول الأدوية التالية قبل البدء بتناول مونتيل:</p><p dir="RTL">&bull; فينوباربيتال (يستخدم لعلاج الصرع)&nbsp;&nbsp;</p><p dir="RTL">&bull; فينايتوين (يستخدم لعلاج الصرع)&nbsp;&nbsp;</p><p dir="RTL">&bull; ريفامبيسين (يستخدم لعلاج السل وبعض العدوى)&nbsp;&nbsp;</p><p dir="RTL">&bull; جيمفيبروزيل (يستخدم لعلاج مستويات الدهون المرتفعة في البلازما)</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>مونتيل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong><strong>والشراب</strong></p><p dir="RTL">يمكن تناول مونتيل 10 ملجم مع أو بدون الطعام.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><p dir="RTL">استخدامه في الحمل</p><p dir="RTL">على النساء الحوامل أو اللواتي يرغبن بالحمل استشارة الطبيب قبل تناول مونتيل.</p><p dir="RTL">فطبيبك سيحدد ما إذا كان بالإمكان تناول مونتيل في ذلك الوقت.</p><p dir="RTL">استخدامه أثناء الرضاعة</p><p dir="RTL">لا يعرف ما إذا كان مونتيل يفرز في حليب المرضعات أم لا. ويجب استشارة الطبيب قبل تناول &quot;مونتيل&quot; إذا</p><p dir="RTL">كنت مرضعة أو تنوين إرضاع طفلك.</p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>السيارات</strong><strong> </strong><strong>وتشغيل</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">لا يتوقع أن يؤثر مونتيل في قدرتك على قيادة السيارات وتشغيل الآلات. وعلى كل حال, فقد تختلف الإستجابة للدواء من شخص لآخر. وبعض الآثار الجانبية (مثل الدوار والدوخة) سجلت بصورة نادرة جدا مع مونتيل قد تؤثر على قدرة المريض على قيادة السيارات أو تشغيل الآلات.</p><p dir="RTL"><strong>معلومات</strong><strong> </strong><strong>مهمة</strong><strong> </strong><strong>حول</strong><strong> </strong><strong>بعض</strong><strong> </strong><strong>مكونات</strong><strong> </strong><strong>مونتيل</strong><strong>:</strong></p><p dir="RTL">يحتوي مونتيل على لاكتوز. إذا سبق وأخبرك طبيبك أنك تعاني من عدم القدرة على تحمل بعض أنواع السكر, فيجب أن تتصل بطبيبك قبل أن تتناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يجب أن تتناول قرص واحد مرة يومياً من مونتيل كما وصف لك الطبيب.</p><p dir="RTL">&bull; يجب تناوله حتى في حالة إختفاء الأعراض أو في نوبات الربو المفاجئة.</p><p dir="RTL">&bull; تناول دائماً مونتيل كما وصف لك الطبيب. وعليك التوثق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&bull; يجب تناوله بالفم.</p><p dir="RTL"><strong>بالنسبة</strong><strong> </strong><strong>للبالغين</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تصل</strong><strong> </strong><strong>أعمارهم</strong><strong> </strong><strong>15 </strong><strong>عاماً</strong><strong> </strong><strong>وأكثر</strong><strong>:</strong></p><p dir="RTL">يجب تناول قرص واحد تركيز 10 ملجم مساءً . ويمكن تناول مونتيل 10 ملجم مع أو بدون الطعام.</p><p dir="RTL">إذا كنت تتناول مونتيل, توثق من أنك لا تتناول منتج آخر يحتوي على نفس المادة الفعالة, مونتيلوكاست.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>الكثير</strong><strong> </strong><strong>من</strong><strong> </strong><strong>مونتيل</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>طريق</strong><strong> </strong><strong>الخطأ</strong></p><p dir="RTL">اتصل بطبيبك فوراً طلبا للمساعدة.</p><p dir="RTL">لم تسجل أي أثار عكسية مع معظم تقارير الجرعة الزائدة. وأكثر الآثار الجانبية التي تم تسجيل وقوعها مع الجرعة الزائدة في الكبار والأطفال شملت ألم البطن, نعاس, عطش, صداع, تقيؤ, وفرط النشاط.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>مونتيل</strong></p><p dir="RTL">حاول أن تتناول مونتيل كما هو موصوف لك. ومع ذلك, إذا نسيت تناول الجرعة, تابع الجدول المعتاد للجرعة وهو قرص واحد مرة يومياً.</p><p dir="RTL">لا تأخذ جرعة إضافية لتعوض الجرعة المنسية.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>مونتيل</strong></p><p dir="RTL">يمكن أن يعالج مونتيل مرض الربو لديك فقط إذا داومت على تناوله.</p><p dir="RTL">من المهم أن تستمر بتناول مونتيل طوال الفترة التي وصفها الطبيب لك. يساعد ذلك في السيطرة على مرض الربو لديك.</p><p dir="RTL">إذا كانت لديك أسئلة إضافية حول استخدام هذا المنتج, فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار الأدوية كلّها، يُمكن أن يُسبّب مونتيل للأطفال أعراضًا جانبية وإن كانت لا تُصيب الجميع.</p><p dir="RTL">في الدراسات السريريّة على أقراص 10 ملجم المغلفة، الأعراض الجانبيّة التي تم الإبلاغ عنها الأكثر شيوعا (التي تحدث لدى 1 من أصل 10 مرضى) التي يُعتقد بأنها مرتبطة بمونتيل هي:</p><p dir="RTL">&bull; ألم في المعدة</p><p dir="RTL">&bull; صُداع</p><p dir="RTL">كانت هذه الأعراض ﺑﺎلأغلب معتدلة، تكررت بوتيرة أعلى لدى المرضى المعالجين بمونتيل، مقارنة بقرص العلاج الذي لا يحتوي على المادة الفعالة</p><p dir="RTL"><strong>الأعراض الجانبيّة الخطيرة</strong></p><p dir="RTL">تحدث مع طبيبك على الفور إذا لاحظت اي من الأعراض الجانبية التالية، والتي قد تكون خطيره، والتي قد تحتاج إلى العلاج الطبي العاجل</p><p dir="RTL"><strong>غير شائعة (تؤثّر على واحد من أصل 100 مريض)</strong></p><p dir="RTL">&bull; الحساسية بما في ذلك تورم في الوجه, الشفتين , اللسان, و/أو الحلق الذي قد يسبب صعوبة في التنفس أو البلع</p><p dir="RTL">&bull; تغييرات في السلوك والمزاج ذات الصلة: الانفعالات بما في ذلك السلوك العدواني أو العداء، والاكتئاب</p><p dir="RTL">&bull; تشنجات</p><p dir="RTL"><strong>نادرة (تؤثّر على واحد من أصل 1000 مريض)</strong><strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة احتمالية النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجفة</p><p dir="RTL">&bull; خفقا ن</p><p dir="RTL"><strong>نادرة جدًّا (تؤثّر على واحد من أصل 10000 مريض)</strong><strong> </strong></p><p dir="RTL">&bull; مزيج من الاعراض مثل المرض المشابه للإنفلونزا، والوخز أو خدر الذراعين والساقين، وتفاقم الاعراض الرئوية و/أو الطفح الجلدي (متلازمة شيرغ ستراوس) (انظر القسم 2)</p><p dir="RTL">&bull; انخفاض عدد الصفائح الدموية في الدم</p><p dir="RTL">&bull; تغييرات في السلوك والمزاج ذات الصلة: الهلوسة، الارتباك، الأفكار الانتحارية</p><p dir="RTL">&bull; تورم (التهاب) الرئتين</p><p dir="RTL">&bull; ردود الفعل الجلدية الشديدة (حمامى عديدة الاشكال) التي قد تحدث دون سابق إنذار</p><p dir="RTL">&bull; التهاب الكبد الوﺑﺎئي</p><p dir="RTL">ﺑﺎلإضافة إلى ذلك، تمّ الابلاغ عن الأعراض الجانبيّة التالية بينما كان الدواء مطروحًا في السوق:</p><p dir="RTL"><strong>شائعة جدًا (تؤثرّ على أ كثر من واحد من أصل 10 مرضى)</strong></p><p dir="RTL"><strong>&bull;</strong> عدوى الجهاز التنفسي العلوي</p><p dir="RTL"><strong>شائعة (تؤثّر على واحد من أصل 10 مرضى)</strong></p><p dir="RTL">&bull; الإسهال والغثيان والقيء</p><p dir="RTL">&bull; الطفح</p><p dir="RTL">&bull; الحمى</p><p dir="RTL">&bull; إرتفاع إنزيمات الكبد</p><p dir="RTL"><strong>غير شائعة (تؤثّر على واحد من أصل 100 مريض)</strong></p><p dir="RTL">&bull; تغيرات في السلوك و المزاج ذات الصلة: اضطراﺑﺎت في الأحلام، بما في ذلك الكوابيس، وصعوبة في النوم، المشي خلال النوم، والتهيج، والشعور ﺑﺎلقلق، والأرق</p><p dir="RTL">&bull; الدوخة والنعاس والوخز/خدر ورعاف</p><p dir="RTL">&bull; جفاف الفم ، عسر الهضم</p><p dir="RTL">&bull; كدمات, حكة</p><p dir="RTL">&bull; الام المفاصل أو العضلات، تشنجات العضلات</p><p dir="RTL">&bull; التبول اللاإرادي في الأطفال الضعف /التعب، والشعور بتوعك، وتورم</p><p dir="RTL"><strong>نادرة (تؤثّر على واحد من أصل 1000 مريض)</strong><strong> </strong></p><p dir="RTL">&bull; تغيرات في السلوك و المزاج ذات الصلة: اضطراب في الاهتمام, ضعف الذاكرة, حركات العضلات غير المنضبط</p><p dir="RTL">نادرة جدًّ ا (تؤثّر على واحد من أصل 10000 مريض)</p><p dir="RTL">&bull; وجود كتل حمراء طرية تحت الجلد، والأكثر شيوعا (حمامى عقدة) على السيقان</p><p dir="RTL">&bull; تغيرات في السلوك و المزاج ذات الصلة: اعراض الوسواس القهري، التاﺗﺎه</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull; يتم حفظها بعيداً عن أيدي ونظرالأطفال.</p><p dir="RTL">&bull; لا تتناول الأقراص بعد تاريخ الانتهاء الموضح بستة أرقام بعد كلمة (EXP) على الشريط. . أول عددين تمثل الشهر, وآخر 4 أعداد تمثل السنة. وبذلك تنتهي صلاحية الدواء بنهاية الشهر المدون.</p><p dir="RTL">&bull; احفظه في العبوة الأصلية لتحميه من الضوء والرطوبة.</p><p dir="RTL">&bull; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعّالةهى مونتيلوكاست. كل قرص يحتوي مونتيلوكاست صوديوم والذي يكافئ 10 ملجم مونتيلوكاست.</p><p dir="RTL">&bull; مكونات أخرى:</p><p dir="RTL">بلورات دقيقة من السيليولوز، لاكتوز أحادي التميه (89.3 ملجم) كروزكارمليلوز الصوديوم (E 463), وستياريت المغنيسيوم.</p><p dir="RTL">الغلاف الرقيق: هايبرميللوز، هيبرولوز (E 463), ثانى أكسيد التيتانيوم (E171), أكسيد الحديد الأحمر والأصفر (E172), وشمع الكرنوبا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص 10 ملجم مونتيل مغلفة بطبقة رقيقة.</p><p dir="RTL">. لونها بيج، مربع مستدير، مغلفة بطبقة رقيقة، مقاسها 7.9 ملم &times; 7.9 ملم مع رقم 117 محفور على وجه واحد</p><p dir="RTL">الأشرطة فى عبوات: 7, 10, 14, 20, 28, 30, 50, 56, 84, 90, 98, 100, 140, 200 قرص.</p><p dir="RTL">الأشرطة (الجرعة الواحدة) فى عبوات: 49, 50 و56 قرص.</p><p dir="RTL">قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة </strong><strong>الصانعة</strong><strong> </strong><strong>:</strong></p><p dir="RTL">أورجانون فارما (المملكة المتحدة) ليميتد، شوتون لين،</p><p dir="RTL">كراملينجتون، نورثمبرلاند، إن إي ٣٣٢ جي يو،</p><p dir="RTL">المملكة المتحد ة</p><p dir="RTL"><strong>إم</strong><strong> </strong><strong>إس</strong><strong> </strong><strong>دى</strong></p><p dir="RTL"><strong>الشركة المالكة لحقوق التسويق</strong><strong> :</strong></p><p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MONTEL 10 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains montelukast sodium, which is equivalent to 10 mg montelukast.
Excipient: Lactose monohydrate 89.3 mg per tablet
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Beige, rounded square, film-coated, size 7.9 mm x 7.9 mm with 117 engraved on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MONTEL is indicated in the treatment of asthma as add-on therapy in those patients with mild to</p><p>moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;asneeded&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom MONTEL is indicated in asthma, MONTEL can also provide symptomatic relief of seasonal allergic rhinitis.</p><p>MONTEL is also indicated in the prophylaxis of asthma in which the predominant component is exercise induced bronchoconstriction.</p><p>Montelukast is indicated for the relief of symptoms of seasonal allergic rhinitis and perennial</p><p>allergic rhinitis in patients 15 years of age and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage for adults 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening.</p><p><em>General recommendations</em>. The therapeutic effect of MONTEL on parameters of asthma control occurs within one day. MONTEL may be taken with or without food. Patients should be advised to continue</p><p>taking MONTEL even if their asthma is under control, as well as during periods of worsening asthma.</p><p>MONTEL should not be used concomitantly with other products containing the same active ingredient, montelukast.</p><p>No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><em>Therapy with MONTEL in relation to other treatments for asthma.</em></p><p>MONTEL can be added to a patient&rsquo;s existing treatment regimen.</p><p><em>Inhaled corticosteroids: </em>Treatment with MONTEL can be used as add-on therapy in patients when inhaled corticosteroids plus &quot;as needed&quot; short acting &beta;-agonists provide inadequate clinical control.</p><p>MONTEL should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p>5-mg chewable tablets are available for paediatric patients 6 to 14 years of age.</p><p><strong><em>Paediatric population</em></strong></p><p>Do not give MONTEL 10 mg film-coated tablets to children less than 15 years of age. The</p><p>safety and efficacy of MONTEL 10 mg film-coated tablets in children less than 15 years has</p><p>not been established.</p><p>5 mg chewable tablets are available for paediatric patients 6 to 14 years of age.</p><p>4 mg chewable tablets are available for paediatric patients 2 to 5 years of age.</p><p>4 mg granules are available for paediatric patients 6 months to 5 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&rsquo; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p>Montelukast should not be substituted abruptly for inhaled or oral corticosteroids.</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases usually, but not always, have been associated with the reduction or withdrawal of oral corticosteroid therapy. The possibility that leukotriene receptor antagonists may be associated with emergence of Churg-Strauss syndrome can neither be excluded nor established. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or</p><p>glucose-galactose malabsorption should not take this medicine.</p><p>Neuropsychiatric events have been reported in adults, adolescents, and children taking Montel</p><p>(see section 4.8). Patients and physicians should be alert for neuropsychiatric events. Patients</p><p>and/or caregivers should be instructed to notify their physician if these changes occur.</p><p>Prescribers should carefully evaluate the risks and benefits of continuing treatment with</p><p>Montel if such events occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products:</p><p>theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is coadministered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.)</p><p><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4- fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Use during pregnancy</em></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>Available data from published prospective and retrospective cohort studies with montelukast</p><p>use in pregnant women evaluating major birth defects have not established a drug-associated</p><p>risk. Available studies have methodologic limitations, including small sample size, in some</p><p>cases retrospective data collection, and inconsistent comparator groups.</p><p>MONTEL may be used during pregnancy only if it is considered to be clearly essential.</p><p><em>Use during lactation</em></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is not known if montelukast is excreted in human milk.</p><p>MONTEL may be used in breast-feeding only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast is not expected to affect a patient&rsquo;s ability to drive a car or operate machinery. However, in very rare cases, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies as follows:</p><p>&bull; 10 mg film-coated tablets in approximately 4000 adult asthmatic patients 15 years of age and older.</p><p>&bull; 10 mg film-coated tablets in approximately 400 adult asthmatic patients with seasonal allergic rhinitis 15 years of age and older.</p><p>&bull; 5 mg chewable tablets in approximately 1750 paediatric asthmatic patients 6 to 14 years of age.</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in asthmatic patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p><strong>Adult and Adolescent Patients</strong></p><p><strong>15 years and older</strong></p><p><strong>(two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric Patients</strong></p><p><strong>6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>Post-marketing Experience</p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse reactions.</p><p>Experience Term, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and</p><p>infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection&dagger;</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic</p><p>system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including</p><p>anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including</p><p>nightmares, insomnia, somnambulism,</p><p>anxiety, agitation including aggressive</p><p>behaviour or hostility, depression,</p><p>psychomotor hyperactivity (including</p><p>irritability, restlessness, tremor&sect;)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention, memory</p><p>impairment, tic</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal</p><p>thinking and behaviour (suicidality),</p><p>obsessive-compulsive symptoms,</p><p>dysphemia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>dizziness, drowsiness,</p><p>paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see</p><p>section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastro-intestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases</p><p>(ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic,</p><p>hepatocellular, and mixed-pattern liver</p><p>injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum, erythema</p><p>multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and</p><p>connective tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle</p><p>cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary</p><p>disorders</p></td><td style="vertical-align:top"><p>enuresis in children</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and</p><p>administration site</p><p>conditions</p></td><td style="vertical-align:top"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the</p><p>clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon</p><p>(&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received</p><p>montelukast, was also reported as Very Common in the patients who received placebo in</p><p>clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast,</p><p>was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exts: 2317-2356-2340.</p><p>Hot line: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with</p><p>montelukast. These include reports in adults and children with a dose as high as 1000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports. The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p>It is not known whether montelukast is dialyzable by peritoneal- or hemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Leukotriene receptor antagonist</p><p><strong>ATC-code: </strong>R03D C03</p><p><strong><u>Mechanism of action</u></strong></p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and latephase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum)</p><p>and in peripheral blood while improving clinical asthma control.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>&nbsp;</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled</p><p>corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>A clinical study was conducted to evaluate montelukast for the symptomatic treatment of seasonal allergic rhinitis in adult asthmatic patients 15 years of age and older with concomitant seasonal allergic rhinitis. In this study, montelukast 10 mg tablets administered once daily demonstrated a statistically significant improvement in the Daily Rhinitis Symptoms score, compared with placebo. The Daily Rhinitis Symptoms score is the average of the Daytime Nasal Symptoms score (mean of nasal congestion, rhinorrhea, sneezing, nasal itching) and the Nighttime Symptoms score (mean of nasal congestion upon awakening, difficulty going to sleep, and nighttime awakenings scores). Global evaluations of allergic rhinitis by patients and physicians were significantly improved, compared with placebo. The evaluation of</p><p>asthma efficacy was not a primary objective in this study.</p><p>&nbsp;</p><p>In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &quot;as-needed&quot; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p>&nbsp;</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>&nbsp;</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption</u></em><em>. </em></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated</p><p>tablet, the mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the Cmax is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p><em><u>Distribution</u></em><em>. </em></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of</p><p>distribution of montelukast averages 8-11 liters. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues.</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Montelukast is extensively metabolized. In studies with therapeutic doses, plasma</p><p>concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an</p><p>oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p>&nbsp;</p><p><em><u>Characteristics in Patients</u></em></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic</p><p>insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>&nbsp;</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and</p><p>triglycerides were observed which were transient in nature. The signs of toxicity in animals were</p><p>increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with</p><p>concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>&nbsp;</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to</p><p>5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose</p><p>Lactose monohydrate</p><p>Croscarmellose sodium</p><p>Hyprolose (E 463)</p><p>Magnesium stearate</p><p>Film coating:</p><p>Hypromellose</p><p>Hyprolose (E 463)</p><p>Titanium dioxide (E 171)</p><p>Red and yellow ferric oxide (E 172)</p><p>Carnauba wax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in polyamide/PVC/aluminium blister package in:</p><p>Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 84, 90, 98, 100, 140 and 200 tablets.</p><p>Blisters (unit doses), in packages of: 49, 50 and 56 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
Organon Pharma (UK) Limited, Shotton Lane,
Cramlington, Northumberland, NE23 3JU,
UK.
Marketing Authorization Holder:
SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2022 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>